LeMaitre Vascular (NASDAQ:LMAT) Posts Quarterly Earnings Results, Meets Estimates

LeMaitre Vascular (NASDAQ:LMAT) issued its quarterly earnings results on Thursday. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting the consensus estimate of $0.49, Zacks reports. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular updated its FY 2025 guidance to 2.150-2.320 EPS and its Q1 2025 guidance to 0.480-0.530 EPS.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock traded down $3.14 during midday trading on Thursday, reaching $99.91. The company had a trading volume of 197,639 shares, compared to its average volume of 137,081. The stock has a fifty day moving average price of $96.75 and a 200 day moving average price of $94.62. The firm has a market cap of $2.25 billion, a PE ratio of 54.60, a P/E/G ratio of 2.22 and a beta of 0.96. LeMaitre Vascular has a fifty-two week low of $62.39 and a fifty-two week high of $109.58.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Barrington Research increased their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price for the company. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.63.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.